Literature DB >> 19788917

Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats.

M R Hutchinson1, K M Ramos, L C Loram, J Wieseler, P W Sholar, J J Kearney, M T Lewis, N Y Crysdale, Y Zhang, J A Harrison, S F Maier, K C Rice, L R Watkins.   

Abstract

Spinal cord microglial toll-like receptor 4 (TLR4) has been implicated in enhancing neuropathic pain and opposing morphine analgesia. The present study was initiated to explore TLR4-mediated pain modulation by intrathecal lipopolysaccharide, a classic TLR4 agonist. However, our initial study revealed that intrathecal lipopolysaccharide failed to induce low-threshold mechanical allodynia in naive rats, suggestive that TLR4 agonism may be insufficient to enhance pain. These studies explore the possibility that a second signal is required; namely, heat shock protein-90 (HSP90). This candidate was chosen for study given its known importance as a regulator of TLR4 signaling. A combination of in vitro TLR4 cell signaling and in vivo behavioral studies of pain modulation suggest that TLR4-enhancement of neuropathic pain and TLR4-suppression of morphine analgesia each likely require HSP90 as a cofactor for the effects observed. In vitro studies revealed that dimethyl sulfoxide (DMSO) enhances HSP90 release, suggestive that this may be a means by which DMSO enhances TLR4 signaling. While 2 and 100 microg lipopolysaccharide intrathecally did not induce mechanical allodynia across the time course tested, co-administration of 1 microg lipopolysaccharide with a drug that enhances HSP90-mediated TLR4 signaling now induced robust allodynia. In support of this allodynia being mediated via a TLR4/HSP90 pathway, it was prevented or reversed by intrathecal co-administration of a HSP90 inhibitor, a TLR4 inhibitor, a microglia/monocyte activation inhibitor (as monocyte-derived cells are the predominant cell type expressing TLR4), and interleukin-1 receptor antagonist (as this proinflammatory cytokine is a downstream consequence of TLR4 activation). Together, these results suggest for the first time that TLR4 activation is necessary but not sufficient to induce spinally mediated pain enhancement. Rather, the data suggest that TLR4-dependent pain phenomena may require contributions by multiple components of the TLR4 receptor complex.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19788917      PMCID: PMC2783248          DOI: 10.1016/j.neuroscience.2009.09.046

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  62 in total

Review 1.  Heat shock proteins: linking danger and pathogen recognition.

Authors:  Anke Osterloh; Minka Breloer
Journal:  Med Microbiol Immunol       Date:  2007-07-19       Impact factor: 3.402

2.  Cell surface molecular chaperones as endogenous modulators of the innate immune response.

Authors:  Martha Triantafilou; Daniel Sawyer; Abdiaziz Nor; Emmanouil Vakakis; Kathy Triantafilou
Journal:  Novartis Found Symp       Date:  2008

3.  Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).

Authors:  Mark R Hutchinson; Yingning Zhang; Kimberley Brown; Benjamen D Coats; Mitesh Shridhar; Paige W Sholar; Sonica J Patel; Nicole Y Crysdale; Jacqueline A Harrison; Steven F Maier; Kenner C Rice; Linda R Watkins
Journal:  Eur J Neurosci       Date:  2008-07       Impact factor: 3.386

4.  Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs.

Authors:  Julie K Olson; Stephen D Miller
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

5.  Heat-shock protein 70 and heat-shock protein 90 associate with Toll-like receptor 4 in response to bacterial lipopolysaccharide.

Authors:  M Triantafilou; K Triantafilou
Journal:  Biochem Soc Trans       Date:  2004-08       Impact factor: 5.407

Review 6.  Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness.

Authors:  Joanna Mika
Journal:  Pharmacol Rep       Date:  2008 May-Jun       Impact factor: 3.024

7.  Effects of dimethyl sulfoxide, pyrrolidine dithiocarbamate, and methylprednisolone on nuclear factor-kappaB and heat shock protein 70 in a rat model of hemorrhagic shock.

Authors:  Roberto Bini; Giorgio Olivero; Antonella Trombetta; Elisabetta Castagna; Paolo Cotogni
Journal:  J Trauma       Date:  2008-04

8.  Increased responsiveness to TLR2 and TLR4 ligands during dimethylsulfoxide-induced neutrophil-like differentiation of HL-60 myeloid leukemia cells.

Authors:  Tsuyoshi Shuto; Takashi Furuta; Judy Cheung; Dieter C Gruenert; Yuko Ohira; Shogo Shimasaki; Mary Ann Suico; Keizo Sato; Hirofumi Kai
Journal:  Leuk Res       Date:  2007-07-30       Impact factor: 3.156

9.  Evidence that opioids may have toll-like receptor 4 and MD-2 effects.

Authors:  Mark R Hutchinson; Yingning Zhang; Mitesh Shridhar; John H Evans; Madison M Buchanan; Tina X Zhao; Peter F Slivka; Benjamen D Coats; Niloofar Rezvani; Julie Wieseler; Travis S Hughes; Kyle E Landgraf; Stefanie Chan; Stephanie Fong; Simon Phipps; Joseph J Falke; Leslie A Leinwand; Steven F Maier; Hang Yin; Kenner C Rice; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2009-08-11       Impact factor: 7.217

Review 10.  Chemokines and the pathophysiology of neuropathic pain.

Authors:  Fletcher A White; Hosung Jung; Richard J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-14       Impact factor: 11.205

View more
  37 in total

1.  Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF.

Authors:  O Saito; C I Svensson; M W Buczynski; K Wegner; X-Y Hua; S Codeluppi; R H Schaloske; R A Deems; E A Dennis; T L Yaksh
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 3.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

Review 4.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

5.  Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Haijun Zhang; Hongmei Zhang; Alyssa K Kosturakis; Abdul Basit Jawad; Patrick M Dougherty
Journal:  J Pain       Date:  2014-04-19       Impact factor: 5.820

6.  Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States.

Authors:  Sarah A Woller; Soo-Ho Choi; Eun Jung An; Hann Low; Dina A Schneider; Roshni Ramachandran; Jungsu Kim; Yun Soo Bae; Dmitri Sviridov; Maripat Corr; Tony L Yaksh; Yury I Miller
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

7.  Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice.

Authors:  Sarah A Woller; Cody Ocheltree; Stephanie Y Wong; Anthony Bui; Yuya Fujita; Gilson Gonçalves Dos Santos; Tony L Yaksh; Maripat Corr
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

8.  Protraction of neuropathic pain by morphine is mediated by spinal damage associated molecular patterns (DAMPs) in male rats.

Authors:  Peter M Grace; Keith A Strand; Erika L Galer; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2017-08-30       Impact factor: 7.217

9.  Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta.

Authors:  S S Lewis; M R Hutchinson; N Rezvani; L C Loram; Y Zhang; S F Maier; K C Rice; L R Watkins
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

Review 10.  Pathological pain and the neuroimmune interface.

Authors:  Peter M Grace; Mark R Hutchinson; Steven F Maier; Linda R Watkins
Journal:  Nat Rev Immunol       Date:  2014-02-28       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.